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Abstract 
Objective: To investigate structural and functional alterations of gray matter (GM) 
and examine their clinical relevance in neuromyelitis optica (NMO) using multimodal 
MRI techniques. 
Methods: Thirty-five NMO and 36 healthy controls (HC) were recruited in this study. 
Cortical lesions were investigated by double inversion recovery (DIR) technique. Five 
voxel-wised MRI measurements were obtained for each participant in the GM 
including GM volume (GMV), fractional anisotropy (FA), mean diffusivity (MD), 
amplitude of low-frequency fluctuation (ALFF), and weighted functional connectivity 
strength (wFCS). Between-group differences, cross-modality relationships and 
MRI-clinical correlations were examined. 
Results: No cortical lesions were found in NMO. Compared to HC, NMO patients 
exhibited significantly decreased GMV in deep GM and cortical regions involving 
visual function and cognition. Diffusion GM abnormalities were widespread in the 
patients. Decreased ALFF and wFCS were observed in the patients in sensorimotor, 
visual, cognition and cerebellar sites. GM structural alterations were correlated with 
cognitive but not physical disability scores of the patients.  
Conclusion: Despite the lack of focal cortical lesions, patients with NMO exhibit 
both structural and functional alterations of GM in cerebrum and cerebellum that 
predominantly involve deep GM, visual, motor and cognitive regions. GM alterations 
are associated with cognitive impairment but not physical disability. 
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Abbreviations: ALFF = amplitude of low-frequency fluctuation; EDSS = expanded 
disability status scale; FA = fractional anisotropy; GMV = gray matter volume; MD = 
mean diffusivity; MRI = magnetic resonance imaging; NMO = neuromyelitis optica; 
PASAT = paced auditory serial addition test; rs-fMRI = resting-state functional MRI; 
wFCS = weighted functional connectivity strength 
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Introduction 
Neuromyelitis optica (Devic’s disease) (NMO) is an astrocytopathy and 
demyelinating disease of central nervous system (CNS), typically without brain 
lesions on conventional MR images, especially in early disease1, 2. However, recent 
neuroimaging studies consistently identify MRI abnormalities in NMO such as 
periependymal lesions surrounding the ventricular system, white matter lesions, and 
lesions involving corticospinal tracts3. Moreover, advanced MRI techniques have 
demonstrated cerebral abnormalities4-7, especially gray matter (GM) alterations8-11, 
which may be the neural basis of cognitive impairments in NMO. 
In NMO, cortical lesions were reported to be absent using double inversion 
recovery (DIR) sequence8. However, using structural and diffusion MRI, both GM 
atrophy9, 12 and microstructural abnormalities13, 14 were separately identified. 
Moreover, functional MRI studies revealed GM abnormalities in both task-evolved15 
and spontaneous brain activity6, 16. These studies advance our understanding of GM 
pathology in NMO, however, most of the above findings are from a single modality 
with differences in samples, clinical features and grouping criteria. Relative to a 
single modality, recent studies have highlighted the importance of multimodal 
integration in revealing neural substrate underlying various brain disorders17, 18. In 
NMO, there are two prior multimodal studies. One investigated structural alterations 
in a small sample (n=8)19, the other focused on the thalamus20. 
In the current study, we systematically investigated structural and functional 
alterations of GM in NMO by combining DIR, high-resolution anatomical MRI, 
diffusion and resting-state functional MRI (rs-fMRI). Furthermore, we examined the 
similarities and differences among different MRI modalities in the locations of 
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NMO-related abnormalities. Finally, clinical correlates of GM structural and 
functional alterations were examined. 
 
Materials and methods 
Participants 
This study was approved by institutional review board of Xuanwu Hospital, Capital 
Medical University and written informed consent was obtained from each participant. 
Forty NMO patients were enrolled in this study from January 2012 to December 2013. 
NMO diagnosis was made according to the 2006 diagnostic criteria2. The 
demographic information and clinical characteristics including Expanded Disability 
Status Scale (EDSS)21, disease duration, number of relapses, mini-mental state 
examination (MMSE), paced auditory serial addition test 2 seconds version (PASAT 
2) and paced auditory serial addition test 3 seconds version (PASAT 3) were recorded 
for all the patients. All the patients’ clinical attacks were restricted to spinal cord and 
optic neuritis. All the patients were relapsing NMO and twenty-seven patients (27/40, 
67.5%) were AQP4 antibody positive measured by an indirect immunofluorescence 
method22. All the patients received steroid treatment, and seven patients received 
additional immunosuppressant therapy. We enrolled 37 gender-, age-, and 
education-matched healthy controls (HC) with no previous history of neurological or 
psychiatric dysfunction and with normal findings on neurological and MRI 
examination. Of note, dataset from a subset of the general population have been used 
to study the thalamus in patients with NMO20.  
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Image acquisition 
All the multimodal MRI scans including conventional MR sequences (T2 and FLAIR), 
double inversion recovery (DIR), high-resolution T1WI, diffusion tensor imaging 
(DTI), resting-state fMRI were performed on a 3.0 Tesla MR system (Siemens 
Magnetom Trio Tim system, Germany). The MRI scans of the NMO patients were 
acquired at least 2 weeks from the last relapse and treatment to minimize their 
confounding effects on subsequent multimodal brain measurements. The median time 
from the last relapse of the patients is 7 months with a range from 2 to 11 months. See 
appendix e-1 for detailed multimodal MR imaging parameters. 
 
Multimodal image analysis 
Based on the multimodal MRI data acquired above, we analyzed WM lesion from 
T2-weighted and FLAIR images, GM lesion from DIR images, GM volume from T1 
images, microstructural integrity (fractional anisotropy, FA and mean diffusivity, MD) 
from diffusion images, and intrinsic functional architecture including amplitude of 
low-frequency fluctuation, ALFF (local oscillation power)23 and weighted functional 
connectivity strength, wFCS (inter-regional functional connectivity over the whole 
brain )24 from rs-fMRI. For details of multimodal imaging preprocessing and measure 
calculation, see appendix e-1. 
 
Statistical analysis 
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Discrete gender data were analyzed using a chi-square test. For other demographic 
and clinical continuous variables, two-sided two-sample t test or Wilcoxon rank sum 
tests were used to assess between-group differences depending on whether they were 
normally distributed (Lilliefors test). For the multimodal MRI measures, a voxel-wise 
general linear model was used to infer between-group differences. To correct for the 
multiple comparisons, a height threshold of p < 0.001 combined with an extent 
threshold of p < 0.05 were employed, which corresponded to a corrected p < 0.05 as 
determined by the Monte Carlo simulations25. Dice coefficient and partial correlation 
analyses were used to estimate cross-modality spatial overlap and quantitative 
relationships for regions showing NMO-related alterations. Partial correlation was 
also used to estimate clinical-MRI relationships in the patients. The effects of age and 
gender were controlled for all MRI-related statistical analyses (i.e., between-group 
comparison and correlation analysis). Gross and subtle head motion parameters were 
treated as extra covariates for rs-fMRI-based analysis. Additionally, we also examined 
effects of clinical attacks (optic neuritis or myelitis) and white matter lesions on 
multimodal MRI alterations in the patients (appendix e-1). 
 
Results 
Demographic and clinical characteristics 
For the current dataset, two NMO patients exhibited relatively large cortical defects 
possibly associated with either old infarcts or trauma, and thus were excluded 
conservatively from further analyses. In addition, three NMO patients and one HC 
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were excluded due to image artifacts by visual inspection. All the demographic and 
clinical characteristics for the remaining 35 NMO patients and 36 HC are summarized 
in Table 1. There were no significant differences in age, gender and educational level 
between the NMO and HC groups (all p > 0.05). The patients had significant lower 
scores in the PASAT 2, PASAT 3 and MMSE compared with the HC (all p < 0.05). 
The cognitive deficits remained significant in NMO after taking educational level as a 
covariate. 
 
WM and GM lesions 
Twenty out of the 35 NMO patients had no WM lesions on cerebral MRI and fifteen 
had non-specific WM lesions (small rounded WM hyperintensities on T2/FLAIR, 
which did not fulfill the McDonald criteria for multiple sclerosis lesions). The mean 
lesion volume was 5.12 (± 3.86) mL for the patients. No cortical lesions were 
identified in the NMO patients based on DIR. 
 
Between-group differences of morphological and microstructural organization 
Compared with the HC, the NMO patients showed significantly decreased GMV in 
the bilateral thalamus, insula, middle temporal gyrus and anterior cingulate, the right 
caudate and inferior frontal gyrus, and the left calcarine (p < 0.05, corrected) (Figure 
1A). For diffusion-based MD and FA, widespread brain regions in both the cerebrum 
and cerebellum were abnormal compared with the HC. Specifically, in addition to the 
regions showing decreased GMV, the patients with NMO showed significantly 
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decreased FA in the precentral gyrus, precuneus and parahippocampal 
gyrus/hippocampus (all bilateral) and the left amygdala (Figure 1B) and the cerebellar 
anterior lobe (bilateral, Figure 2A). A similar but even more diffuse pattern of 
increased MD in the patients compared with the HC was observed. The greatest 
abnormalities were found in the medial prefrontal, lateral temporal cortex and deep 
GM structures (Figure 1C and Figure 2B). 
 
Between-group differences of functional measurements 
Limited and regionally specific NMO-related alterations were found in the functional 
scans. Specifically, for the ALFF, significant decreases were mainly observed in 
sensorimotor (e.g., the bilateral paracentral lobule, the right supplementary motor area 
and precentral gyrus) and visual cortex (e.g., the right inferior and middle occipital 
gyrus) (p < 0.05, corrected) (Figure 1D), while for the wFCS, NMO-related decreases 
were primarily observed in visual (e.g., the superior occipital gyrus and cuneus, the 
right fusiform) and cognition-related areas (e.g., the bilateral middle cingulate gyrus, 
and the left anterior cingulate gyrus) and the cerebellum (p < 0.05, corrected) (Figure 
1E and Figure 2C). 
 
Cross-modality relationship 
Figure 3A shows spatial overlaps among the five multimodal MRI-based measures in 
revealing NMO-related GM alterations. The most frequently affected regions included 
deep GM structures (e.g., the bilateral thalamus and caudate), medial prefrontal cortex 
 11 
and temporal lobe locations (e.g., hippocampus/parahippocampal gyrus and superior 
temporal gyrus) and insula. Further pairwise cross-modality comparisons showed that 
the largest spatial overlap was observed between FA and MD (dice coefficient = 
0.289), followed by GMV and MD (dice coefficient = 0.179) and GMV and FA (dice 
coefficient = 0.087). The spatial overlaps between other combinations were relatively 
low. Of note, there was no common region that simultaneously exhibited GMV and 
functional (ALFF/wFCS) alterations in NMO (Figure 3B). We further quantified 
pairwise cross-modality correlations in the regions (cluster size > 20 voxels) that 
simultaneously exhibited NMO-related alterations (Figure 3C) in the patient group. 
Significantly positive correlations were observed between GMV and FA (r = 0.481, p 
= 0.005, mean across clusters) and between FA and wFCS (r = 0.398, p = 0.022, mean 
across clusters), and significantly negative correlations were observed between GMV 
and MD (r = -0.491, p = 0.004, mean across clusters) and between FA and MD (r = 
-0.548, p < 0.001, mean across clusters) (Figure 3D). 
 
MRI-clinical relationship 
For the NMO patients, significant correlations were observed between structural brain 
measures (GMV, FA and MD) and clinical characteristics (p < 0.05, False Discovery 
Rate corrected) in multiple GM structures. In detail, the PASAT 2 was correlated with 
GMV in the left thalamus, FA in the brainstem and MD in the right thalamus; the 
PASAT 3 was associated with MD in the right parahippocampus and superior 
temporal gyrus; the disease duration was correlated with FA and MD in the left 
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parahippocampus/hippocampus; and the number of relapses was related to MD in the 
bilateral cuneus. The scatter plots of all these correlations are shown in Figure 4. No 
significant correlations were observed between the EDSS (including cerebellar 
functional system score) and the multimodal MRI measurements in the patients. There 
were also no significant effects of clinical attacks (optic neuritis or myelitis) and 
white matter lesions on the multimodal MRI measurements in the patients (p > 0.05, 
False Discovery Rate corrected).  
 
Discussion 
In the current study, we examined GM structural and functional alterations in NMO 
by employing multimodal quantitative MRI techniques. The main findings can be 
summarized as: 1) no focal cortical lesions were found in NMO patients; 2) both 
structural and functional alterations in GM were identified in NMO, with structural 
abnormalities being much more extensive than functional changes. Predominantly 
affected areas included deep GM nuclei and cortical regions involved in vision, motor 
function and cognition; 3) multimodal MRI provided complementary information by 
capturing NMO-induced GM alterations, with DTI revealing much more widespread 
abnormalities than other structural and functional MRI measures; and 4) structural 
GM alterations, particularly microstructural abnormalities, were correlated with the 
patients’ cognitive impairment, but not physical disability. 
Nearly half of the included NMO patients showed non-specific WM lesions, 
while none exhibited cortical lesions in the current study. These findings are 
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consistent with previous findings5, 8, 26 and confirm that non-specific WM lesions (not 
fulfill the criteria for multiple sclerosis lesions) and the absence of cortical lesions is 
MRI features of NMO distinguishing them from multiple sclerosis10. 
Structural and functional alterations were observed in GM in NMO. Specifically, 
the VBM analysis revealed regional GM atrophy in multiple regions. This is 
consistent with previous studies reporting GM atrophy in NMO in terms of either 
GMV10-12 or cortical thickness8, 9. Specifically, NMO-related GM atrophy principally 
occurred in deep GM nuclei and several cortical areas related to vision, sensorimotor 
and cognition such as anterior cingulate cortex. This atrophy could be caused by 
primary cortical pathology such as an inflammatory-degenerative process induced by 
Aquaporin-4 (AQP4) or secondary trans-synaptic degeneration triggered by axonal 
loss in lesions in the optic nerve and spinal cord. 
Microstructural abnormalities have been previously reported to be widespread in 
WM fibers4, 27. Using a diffusivity histogram13 or ROI analysis14, significant diffusion 
changes have also been observed in the normal appearing GM in NMO. Our study 
extends previous findings by using a voxel-based whole-brain method showing that 
diffusion changes are widely distributed in brain areas implicated in visual, 
sensorimotor and cognitive functions. Given that a serum immunoglobulin G 
autoantibody (NMO-IgG) selectively binds to AQP428 in NMO, we speculate the 
disruption of water homeostasis may be one key pathophysiological basis for the 
observed diffusion changes. As a novel finding, diffusion abnormalities were also 
found in the cerebellum, possible factors contributing to cerebellar diffusion 
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abnormalities in NMO include primary pathogenic effect of the anti-AQP4 antibody 
since AQP4 is highly expressed in cerebellum29, and secondary degeneration since the 
cerebellum has direct and dense connections to the spinal cord30.  
To examine functional architecture, we employed ALFF and wFCS to study local 
activity fluctuations and interregional connectivity in NMO, respectively. Our results 
showed subtle functional alterations (both for local neural activity [ALFF] and for 
functional coupling [wFCS]), mainly in motor, vision and cognition related areas, 
corresponding to the symptoms in NMO, and consistent with previous findings6, 11. 
Interestingly, the cerebellum also showed decreased wFCS in NMO, proposing the 
cerebellum as a possible NMO-related disconnection site. Further studies are needed 
to confirm our newly described cerebellar MRI abnormalities.  
We observed that most of the brain areas with decreased GMV in NMO were 
those also harboring diffusion changes, and significant associations were observed 
between regional FA/MD and GMV in the patients. Given that no focal cortical 
pathology was observed on the DIR images in the current study and on ultra-high 
field MR images in previous studies26, the observed volumetric and microstructural 
alterations of deep GM and cortical areas may commonly reflect trans-synaptic 
degeneration caused by axonal loss in the lesions31. However, functional MRI changes 
were partly limited to areas with diffusion abnormalities in the absence of 
morphological alterations, implying the existence of additional and independent 
mechanism for functional alterations in NMO. The tight 
microstructural-morphological and weak structural-functional associations of 
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multimodal MRI changes in NMO are consistent with our previous studies in multiple 
sclerosis and/or NMO20, 32 and suggest that structural and functional fusion analysis 
could provide unique and complementary information on these two diseases. Notably, 
there are few studies currently that directly compare these two diseases from a 
multimodal integrative perspective, which is an important topic in the future. Overall, 
our results indicate that NMO is associated with common and distinct GM alterations 
among different MRI modalities and microstructural diffusion abnormalities may be 
the most sensitive measures to detect early and subtle GM damages in NMO. Future 
studies are needed to provide deeper insights into these findings by establishing 
sequential or causal relationships among NMO-related multimodal alterations with 
the help of computational modeling and simulation. 
Significant correlations with cognitive scores of the patients were found for GM 
structural changes, particularly microstructural abnormalities, in several brain areas, 
such as thalamus and parahippocampus. This implies that GM structural changes may 
serve as potential biomarkers for assessing and monitoring cognitive impairment in 
NMO although longitudinal studies are required. No correlations were observed 
between physical disability in terms of EDSS and multimodal MRI measurements, 
suggesting other factors (i.e., spinal cord pathology) rather than brain GM damage 
account for the largest proportion of physical disability in NMO. Notably, the 
diffusion abnormalities of cognition related brain areas (e.g., 
parahippocampus/hippocampus) were correlated with disease duration and cognitive 
scores, while diffusion alterations in visual areas were correlated to the number of 
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relapses, indicating different pathological mechanisms underlying GM microstructural 
damage in NMO. Collectively, these findings highlight a neuropathological and 
neurocognitive significance of GM changes especially in microstructure in 
understanding NMO.  
The present study had several limitations. First, this was a cross-sectional study, 
and longitudinal studies are required to assess whether distinct longitudinal changes in 
GM predict clinical disease progression. Second, the cognitive assessment of the 
participants only included MMSE and PASAT, which limited a more comprehensive 
examination of MRI-cognition correlates. A more systematical cognitive evaluation 
such as Minimal Assessment of Cognitive Function in MS33 is planned for a future 
study. Third, all the patients were treated in the current study, and thus we cannot 
exclude the possibility of treatment effects on our findings of multimodal MRI 
measures and neuropsychological tests. Future studies will help clarify this issue by 
exploring brain changes of NMO patients following different treatment strategies or 
recruiting treatment-naïve patients. Fourth, the current study utilized rs-fMRI to 
characterize NMO-related alterations of intrinsic functional brain architecture. 
Considering that NMO is associated with cognitive dysfunction in multiple domains34, 
it is interesting in the future to examine functional brain alterations of NMO patients 
while performing cognitive tasks. Finally, the current study mainly focused on local 
brain architecture in NMO. Given the highly integrative nature of the brain35, it will 
be an interesting topic in future to explore NMO-related cortical reorganization from a 
network perspective.  
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In conclusion, despite the lack of focal cortical lesions, patients with NMO 
exhibited both structural and functional alterations of GM in cerebrum and cerebellum 
that predominantly involved deep GM, visual, motor and cognitive regions. 
Multimodal MRI techniques were complementary to capture NMO-related GM 
abnormalities, but DTI changes were the most widespread. GM alterations, especially 
diffusion abnormalities were associated with both disease duration and number of 
relapses, and correlated with cognitive impairment but not physical disability in 
NMO. 
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Tables and Figures 
Table 1. Demographics and clinical characteristics of the participants 
 HC (n= 36) NMO (n=35) p-value 
Age (years) 30 (21 - 59) 38 (18 - 56) 0.158a 
Gender (M/F) 8/28 5/30 0.387b 
Education (years) 14.167 ± 3.385 12.914 ± 3.175 0.113c 
EDSS NA 4 (1 - 6) NA 
Disease duration (months) NA 48.14 ± 45.77 (1 - 180) NA 
Number of relapse NA 4.43 ± 2.58 (2 - 12) NA 
Time from last relapse (months) NA 7 (2 - 11) NA 
MMSE 29 (20 - 30) 26 (22 - 30) < 0.001a 
PASAT 2 47.44 ± 7.01 (27 - 58) 36.20 ± 9.57 (20 - 56) < 0.001c 
PASAT 3 53.58 ± 5.06 (40 - 60) 41.49 ± 8.83 (25 - 60) < 0.001c 
Dare presented as mean ± standard (minimum - maximum) or median (minimum - 
maximum) depending on the normality (Lilliefors test). HC = healthy control; NMO = 
neuromyelitis optica; M = male; F = female; EDSS = Expanded Disability Status 
Scale; MMSE = Mini-Mental State Examination; PASAT 2 = paced auditory serial 
addition test 2 seconds version; PASAT 3 = paced auditory serial addition test 3 
seconds version; NA = not available. 
aThe p-values were obtained using two-tail Wilcoxon rank sum tests. 
bThe p-values was obtained using two-tail Pearson chi-square test. 
cThe p-values were obtained using two-sample two-tail t tests. 
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Figure Legends 
Figure 1. Between-group differences in GMV (A), FA (B), MD (C), ALFF (D) and 
wFCS (E) in the cerebrum. 
Abbreviations: ALFF = amplitude of low-frequency fluctuation; GMV = grey matter 
volume; FA = fractional anisotropy; GMV = gray matter volume; MD = mean 
diffusivity; wFCS = weighted functional connectivity strength. 
 
Figure 2. Between-group differences in FA (A), MD (B) and wFCS (C) in the 
cerebellum. 
Abbreviations: FA = fractional anisotropy; MD = mean diffusivity; wFCS = weighted 
functional connectivity strength. 
 
Figure 3. Cross-modality relationships.  
A, spatial overlap map among the five measures in revealing NMO-related alterations.  
B, pairwise dice coefficients in the spatial extent. C, pairwise spatial overlap maps. D, 
pairwise correlations in the patient group. 
*, P < 0.05. 
**, P < 0.01. 
***, P < 0.005. 
Abbreviations: ALFF = amplitude of low-frequency fluctuation; GMV = grey matter 
volume; FA = fractional anisotropy; MD = mean diffusivity; wFCS = weighted 
functional connectivity strength. 
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Figure 4. Relationships between multimodal MRI-based measures and clinical 
variables. 
Abbreviations: CAL = calcarine; FA = fractional anisotropy; GMV = grey matter 
volume; HIP = hippocampus; MD = mean diffusivity; NR = number of relapse; 
PASAT = paced auditory serial addition test; PHG = parahippocampus; STG = 
superior temporary gyrus; THA = thalamus. 
 
